

AXIM BIOTECHNOLOGIES, INC.

Form 8-K

March 22, 2017

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): March 21, 2017**

**AXIM BIOTECHNOLOGIES, INC.**

(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction of  
incorporation)

000-54296  
(Commission File Number)

27-4092986  
(I.R.S. Employer Identification No.)

18 E 50th St 5th Floor,  
New York, NY  
(Address of principal executive offices)

10022  
(Zip Code)

Edgar Filing: AXIM BIOTECHNOLOGIES, INC. - Form 8-K

(212) 751-0001

(Registrant's telephone number, including area code)

(Former name if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- . Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - . Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - . Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - . Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 - Regulation FD Disclosure**

On March 21, 2017, AXIM Biotechnologies, Inc. issued a press release which announced that the company had retained the services of Ora®, Inc., a global Contract Research Organization, to perform the company's upcoming product development and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 - Financial Statements and Exhibits**

(d) Exhibits

99.1 Press Release

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AXIM BIOTECHNOLOGIES, INC.**

Dated: March 21, 2017

By:

*/s/ Dr. George E. Anastassov*  
Name: Dr. George E. Anastassov  
Chief Executive Officer

